Literature DB >> 2417079

In-vitro inhibition of LAV/HTLV-III infected lymphocytes by dithiocarb and inosine pranobex.

A Pompidou, D Zagury, R C Gallo, D Sun, A Thornton, P S Sarin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2417079     DOI： 10.1016/s0140-6736(85)92585-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Treatment of the acquired immune deficiency syndrome.

Authors:  S Gupta; M S Gottlieb
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

2.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

3.  Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.

Authors:  C De Simone; F Albertini; M Almaviva; G Angarano; F Chiodo; P Costigliola; S Delia; A Ferlini; F Gritti; G Mazzarello
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 4.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.